ADVERTISEMENT

AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes

Marlene Busko   |   Conference Report   |   29 June 2021
ADVERTISEMENT

The AMPLITUDE-O phase 3 trial showed that investigational drug efpeglenatide (Sanofi/Hanmi Pharmaceutical) — an exendin-based glucagon-like peptide-1 (GLP-1) receptor agonist — was safe and reduced the risk of worsening renal and cardiovascular outcomes in patients with type 2 diabetes at high cardiovascular risk.

That is, in patients with type 2 diabetes and...

          

March Challenge

Ends in 4d 1h
left
right

Topic Challenges

left
right